Antidepressant Safety Concerns Not Impacting Forest's SSRI Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 conference call